Bertino
Impact in
- Otorhinolaryngology top 5%
- Head and Neck Cancer Studies
- Oncology top 10%
- Cancer-related Molecular Pathways
Papers in
- Oncology 9
- Cancer-related Molecular Pathways 3
- Cancer Diagnosis and Treatment 2
-
- Lung Cancer Treatments and Mutations 8
- Co-authors
- Mitchell Ms (3 shared papers)Papac Rj (2 shared papers)Martin Levitt (2 shared papers)Enrico Mini (1 shared paper)Thomas Ed (1 shared paper)Kaplan (1 shared paper)Rose J. Papac (1 shared paper)P. V. Danenberg (1 shared paper)
- Journals
- Journal of Investigative Dermatology (1 paper)电子学报：英文版 (1 paper)PubMed (23 papers)世界胃肠病学杂志：英文版（电子版） (1 paper)世界胃肠病学杂志：英文版 (1 paper)
- Partner nations
- United StatesItaly
In The Last Decade
Bertino
27 papers receiving 480 citations
Peers
Comparison fields: 5 of 79
- Otorhinolaryngology 57
- Oncology 204
- Hematology 71
- Public Health, Environmental and Occupational Health 126
- Pathology and Forensic Medicine 73
Countries citing papers authored by Bertino
This map shows the geographic impact of Bertino's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bertino with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bertino more than expected).
Fields of papers citing papers by Bertino
This network shows the impact of papers produced by Bertino. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bertino. The network helps show where Bertino may publish in the future.
Co-authors
The 25 scholars most cited alongside Bertino, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 27 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Improved therapeutic index of methotrexate with "leucovorin rescue". | 1973 | 133 |
| 2 | Current understanding of methotrexate pharmacology and efficacy in acute leukemias. Use of newer antifolates in clinical trials. | 2001 | 72 |
| 3 | TECHNIQUES FOR STUDY OF RESISTANCE TO FOLIC ACID ANTAGONISTS. | 1964 | 52 |
| 4 | Effectiveness of high-dose infusions of methotrexate followed by leucovorin in carcinoma of the head and neck. | 1968 | 51 |
| 5 | Transfection of wild-type but not mutant p53 induces early monocytic differentiation in HL60 cells and increases their sensitivity to stress. | 1995 | 42 |
| 6 | Sequential methotrexate and 5-fluorouracil: mechanisms of synergy. | 1983 | 38 |
| 7 | Methotrexate and 5-fluorouracil in sequence in squamous head and neck cancer. | 1983 | 23 |
| 8 | Clinical and pharmacological evaluation of triazinate in humans. | 1976 | 21 |
| 9 | Randomized study comparing doxorubicin, cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (ACOMLA) with cyclophosphamide, doxorubicin, vincristine, prednisone, and bleomycin (CHOP-B) in the treatment of diffuse histiocytic lymphoma. | 1982 | 18 |
| 10 | Head and neck cancer. 3. Toxicity of 24-hour infusions of methotrexate (NSC-740) and protection by leucovorin (NSC-3590) in patients with epidermoid carcinomas. | 1967 | 17 |
| 11 | Natural resistance to methotrexate in human acute nonlymphocytic leukemia. | 1977 | 17 |
| 12 | Inhibition of two human tumor cell lines by antimetabolites of coenzyme Q10. | 1978 | 10 |
| 13 | Pretreatment of endometrial carcinoma cell lines with butyrate results in upregulation of Bax and correlates with potentiation of radiation induced cell kill. | 2001 | 8 |
| 14 | Possible hazards of working with cytotoxic agents: a review of the literature. | 1981 | 8 |
| 15 | Symposium on immunosuppressive drugs. Folate antagonists: some biochemical and pharmacological considerations. | 1967 | 7 |
| 16 | Enzymes of the thymidylate cycle as targets for chemotherapeutic agents: mechanisms of resistance. | 1992 | 6 |
| 17 | Treatment of advanced neoplastic disease with 1-(2-chlorethyl)-3-cyclohexyl-1-nitrosourea (CCNU; NSC-79037). | 1973 | 5 |
| 18 | Rationale for the selection of chemotherapeutic agents. | 1969 | 5 |
| 19 | Detection of Monoclonal Lymphoid Subpopulations in Clinical Specimens by Pcr and Conformational Polymorphisms of Crna Molecules | 1992 | 4 |
| 20 | Transfection of a nonactive site mutant murine DHFR cDNA (the tryptophan 15 mutant) into Chinese hamster ovary and mouse marrow progenitor cells imparts MTX resistance in vitro. | 1994 | 4 |
About Bertino
Bertino is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Otorhinolaryngology and Organic Chemistry, having authored 27 papers that have together received 550 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (8 papers), Head and Neck Cancer Studies (4 papers), Cancer-related Molecular Pathways (3 papers), Liver Disease Diagnosis and Treatment (2 papers), Cancer Diagnosis and Treatment (2 papers), Synthesis and Characterization of Heterocyclic Compounds (2 papers), Lymphoma Diagnosis and Treatment (2 papers) and Cancer Research and Treatments (2 papers). The work is most often cited by research in Otorhinolaryngology (57 citations), Oncology (204 citations), Hematology (71 citations), Public Health, Environmental and Occupational Health (126 citations) and Pathology and Forensic Medicine (73 citations). Bertino has collaborated with scholars based in United States and Italy. Frequent co-authors include Mitchell Ms, Papac Rj, Martin Levitt, Enrico Mini, Thomas Ed, Kaplan, Rose J. Papac, P. V. Danenberg, Barbara Schnieders and Jingfang Ju. Their work appears in journals such as Journal of Investigative Dermatology, 电子学报：英文版, PubMed, 世界胃肠病学杂志：英文版（电子版） and 世界胃肠病学杂志：英文版.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.